New results from the SELECT2 trial also show benefit of the procedure in a large range of ischemic core sizes and in patients transferred from an outside hospital.
In the wake of Vera Therapeutics announcing positive 72-week data from the phase 2b ORIGIN trial, we sat down with lead investigator Richard Lafayette, MD, to learn more about how he interprets the latest data from the atacicept program in IgA nephropathy.
In a short time online, organizations can capture more patient concerns, reduce more open cases and improve staff experiences, say Alpa Vyas of Stanford Healthcare and Dr. Adrienne Boissy of Qualtrics and the Cleveland Clinic.
The FDA has granted full approval to Tarpeyo (budesonide) to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy who are at risk for disease progression.
The FDA has granted full approval to Tarpeyo (budesonide) to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy who are at risk for disease progression.